论文信息 - Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial - 字舞流文

Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial

Jashin J. Wu | L. Spelman | A. Rossi | B. Shumel | T. Etoh | H. Zhang | Jerry Tan

[1] K. Thomas,et al. Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2] I. Dávila,et al. Dupilumab: A New Paradigm for the Treatment of Allergic Diseases. , 2018, Journal of investigational allergology & clinical immunology.

[3] H. Williams,et al. Measuring long-term disease control in patients with atopic dermatitis: A validation study of well-controlled weeks , 2017, The Journal of allergy and clinical immunology.

[4] G. Yancopoulos,et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.

[5] D. Margolis,et al. Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. , 2016, Journal of the American Academy of Dermatology.